List view / Grid view
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
Baricitinib demonstrated superiority over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis disease activity...
Lilly and Incyte have announced positive topline results from the fourth successful Phase 3 study (RA-BEAM ) of baricitinib.
13 October 2015 | By Victoria White
Preclinical evidence suggests that the combination of these two agents may lead to an enhanced anti-tumour immune response...
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
19 August 2015 | By Victoria White
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine's 2015 list of the "World's Most Innovative Companies"...
14 April 2015 | By Victoria White
Incyte's base for European clinical development operations is to be based in Geneva, Switzerland. Incyte is to occupy a 9,000 sq. ft. facility by mid-2015...
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response…
28 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...
14 May 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation...
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
